ROBERT LEETH: Open Payments
NPI 1881657237 · COEUR D ALENE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,002 in 88 payments from 15 companies in 2025. Trend: 2023 $139 · 2024 $806 · 2025 $3,002
Food & beverage: $2,219Travel & lodging: $783
| Company | Payments | Amount |
|---|---|---|
| Neuronetics, Inc. | 3 | $1,126 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $489 |
| Janssen Pharmaceuticals, Inc | 6 | $314 |
| Otsuka America Pharmaceutical, Inc. | 12 | $195 |
| Teva Pharmaceuticals USA, Inc. | 7 | $181 |
| Lundbeck LLC | 6 | $129 |
| Axsome Therapeutics, Inc. | 8 | $110 |
| Alkermes, Inc. | 5 | $105 |
| Supernus Pharmaceuticals, Inc. | 2 | $80 |
| Neurocrine BioSciences, Inc. | 3 | $68 |
Products named: NEUROSTAR TMS THERAPY SYSTEM, CAPLYTA, INVEGA SUSTENNA, REXULTI, AUSTEDO XR, LYBALVI, Qelbree, UZEDY.
Industry payments across ID — which companies pay providers there.
